Editor’s note: This story has been updated since its original publication to include additional information about lawsuits Blue Cross and Blue Shield of Louisiana and HMO Louisiana filed against pharmaceutical executives companies.
Blue Cross and Blue Shield of Louisiana and HMO Louisiana have filed seven additional lawsuits to recoup overcharges from pharmaceutical companies engaging in an alleged price-fixing conspiracy of generic drugs.
The lawsuits also were filed on Tuesday in the U.S. District Court for the Eastern District of Pennsylvania. Under the name Louisiana Health Service Indemnity Company, Blue Cross and HMO Louisiana filed five other lawsuits against more a dozen companies in the same district court on Tuesday. There are a total of 12 lawsuits.
The additional lawsuits concern generics of Glyburide, Clomipramine, Fluocinonide, Propranolol, Prevastatin, Divalproex ER, and Desonide. The drugs treat conditions ranging from diabetes to obsessive compulsive disorder to atopic dermatitis.
The other lawsuits concern generics of Lidocaine, Prilocaine, Ursodiol, Clobetasol, Levothyroxine, Doxycycline and Digoxin.
As with the other suits, Blue Cross and HMO Louisiana are seeking a class action status and are requesting a jury trial. They accuse the defendants of selling “hundreds of millions of dollars worth” of the generics every year, and of having unexplained price hikes in markets they control.
The insurers have sued nearly two dozen companies, including: Aurobindo Pharma USA, Citron Pharma, Jeffrey A. Glazer, Jason T. Malek Pliva Inc., UDL Laboratories Inc., ENDO International PLC, Breckenridge Pharmaceuticals Inc., Upsher-Smith Laboratories Inc., Apotex Corp., Dr. Reddy’s Laboratories Inc., Glenmark Pharmaceuticals Inc., Lupin Pharmaceuticals Inc. and Zydus Pharmaceuticals (USA) Inc.
—Alexandria Burris
